Shiitake Mushroom Intake Tied to Improved Human Immunity

Share this content:
Shiitake Mushroom Intake Tied to Improved Human Immunity
Shiitake Mushroom Intake Tied to Improved Human Immunity

MONDAY, April 27, 2015 (HealthDay News) -- Regular consumption of Lentinula edodes (shiitake) mushrooms is associated with improved human immunity, according to a study published online April 11 in the Journal of the American College of Nutrition.

Xiaoshuang Dai, from the University of Florida in Gainesville, and colleagues examined whether consumption of whole, dried shiitake mushrooms could improve human immune function in a study involving 52 healthy adults aged 21 to 41 years. Participants in the four-week, parallel-group study consumed 5 or 10 g mushrooms daily. Blood was drawn and saliva and serum were collected before and after the study.

The researchers observed increased ex vivo proliferation of γδ-T cells and natural killer T-cells (60 percent and two-fold increase, respectively; both P < 0.0001) with four weeks of mushroom consumption. A greater ability to express activation receptors was seen in both cell types with mushroom consumption. There was an increase in secretory immunoglobulin A in saliva and a reduction in C-reactive protein in serum. There was a significantly different pattern of cytokines secreted before and after mushroom consumption, with increased interleukin (IL)-4, IL-10, tumor necrosis factor α, and IL-1α levels, and decreased macrophage inflammatory protein-1α/chemokine C-C ligand 3 levels with consumption.

"Regular L. edodes consumption resulted in improved immunity, as seen by improved cell proliferation and activation and increased sIgA production," the authors write.

Funding was provided by the U.S. Mushroom Council and the Australian Mushroom Growers Association.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths